BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Internet Bookkeeping Programming for Consultants - 2This Tiny Neon Frog Dwells in the Clouds
- 3Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- 4It May Take a Year to Restore Abu Dhabi Aluminum Output, EGA Says
- 5Report in relation to renaming Herzog Park set to be withdrawn
- Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- Quantum Computing’s Next Major Breakthroughs Could Come From Australia
- Boeing's troubled capsule won't carry astronauts on next space station flight
- Top 15 Online Entertainment Stages for Individual Marking
- Monetary Versatility: Get ready for Life's Unforeseen Difficulties
- From Loner to Force to be reckoned with: Individual Accounts of Change
- NAFFIC and Aware to Launch First China-Europe Digital Product Passport
- Schools to start reopening after Nigeria mass abduction
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
